G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests

Domingo, Gonzalo J, Satyagraha, Ari Winasti, Anvikar, Anup, Baird, Kevin, Bancone, Germana, Bansil, Pooja, Carter, Nick, Cheng, Qin, Culpepper, Janice, Eziefula, Chi, Fukuda, Mark, Green, Justin, Hwang, Jimee, Lacerda, Marcus, McGray, Sarah, Menard, Didier, Nosten, Francois, Nuchprayoon, Issarang, Oo, Nwe Nwe, Bualombai, Pongwit, Pumpradit, Wadchara, Qian, Kun, Recht, Judith, Roca, Arantxa, Satimai, Wichai, Sovannaroth, Siv, Vestergaard, Lasse S and Von Seidlein, Lorenz (2013) G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Malaria Journal, 12 (391). pp. 1-12. ISSN 1475-2875

[img] PDF - Published Version
Available under License Creative Commons Attribution.

Download (469kB)

Abstract

Malaria elimination will be possible only with serious attempts to address asymptomatic infection and chronic infection by both Plasmodium falciparum and Plasmodium vivax. Currently available drugs that can completely clear a human of P. vivax (known as “radical cure”), and that can reduce transmission of malaria parasites, are those in the 8-aminoquinoline drug family, such as primaquine. Unfortunately, people with glucose-6-phosphate dehydrogenase (G6PD) deficiency risk having severe adverse reactions if exposed to these drugs at certain doses. G6PD deficiency is the most common human enzyme defect, affecting approximately 400 million people worldwide. Scaling up radical cure regimens will require testing for G6PD deficiency, at two levels: 1) the individual level to ensure safe case management, and 2) the population level to understand the risk in the local population to guide Plasmodium vivax treatment policy. Several technical and operational knowledge gaps must be addressed to expand access to G6PD deficiency testing and to ensure that a patient’s G6PD status is known before deciding to administer an 8-aminoquinoline-based drug.

In this report from a stakeholder meeting held in Thailand on October 4 and 5, 2012, G6PD testing in support of radical cure is discussed in detail. The focus is on challenges to the development and evaluation of G6PD diagnostic tests, and on challenges related to the operational aspects of implementing G6PD testing in support of radical cure. The report also describes recommendations for evaluation of diagnostic tests for G6PD deficiency in support of radical cure.

Item Type: Article
Schools and Departments: Brighton and Sussex Medical School > Global Health and Infection
Subjects: R Medicine
Depositing User: Deborah Miller
Date Deposited: 28 Feb 2019 17:01
Last Modified: 28 Feb 2019 17:01
URI: http://sro.sussex.ac.uk/id/eprint/82269

View download statistics for this item

📧 Request an update